Applications of the Whole-Cell System in the Efficient Biosynthesis of Heme

Heme has a variety of functions, from electronic reactions to binding gases, which makes it useful in medical treatments, dietary supplements, and food processing. In recent years, whole-cell system-based heme biosynthesis methods have been continuously explored and optimized as an alternative to the low-yield, lasting, and adverse ecological environment of chemical synthesis methods. This method relies on two biosynthetic pathways of microbial precursor 5-aminolevulinic acid (C4, C5) and three known downstream biosynthetic pathways of heme. This paper reviews the genetic and metabolic engineering strategies for heme production in recent years by optimizing culture conditions and techniques from different microorganisms. Specifically, we summarized and analyzed the possibility of using biosensors to explore new strategies for the biosynthesis of heme from the perspective of synthetic biology, providing a new direction for future exploration.


Introduction
Heme is a complex composed of ferrous ions (Fe 2+ ) and protoporphyrin IX (PPIX), a heterocyclic macrocyclic organic compound, forming a heme-Fe 2+ complex that can bind to O 2 and CO molecules. In addition, ferric iron (Fe 3+ ) is also incorporated into PPIX, resulting in heme-Fe 3+ complexes that not only bind to NO and SH (SSH) molecules but are often used in the construction of heme sensors. The Lewis acid, hydrophobic, and redox activities of heme enable it to play multiple roles in many biological functions, including catalytic, electron transfer, gas sensing, and transport functions as a cofactor for a variety of proteins, as well as a signaling molecule regulating transcription factors, kinases, ion channels, and cell surface receptors [1][2][3] (Figure 1). For example, heme protein P450s catalyzes ≥ 95% of the reactions known to occur through REDOX chemistry [4]. It can catalyze the specific addition of oxygen atoms on chemical scaffolds. This allows it to play a key role in the production of important molecules using microbial fermentation processes and also in the synthesis of valuable chemicals (e.g., antibiotics, drug metabolites, Steroids and terpenes) have further applications [5], which have given them a leading role in medicine [4]. Furthermore, heme is the most abundant form of iron in mammals, capable of reaching 95% of the total iron quota in the human body, usually 3-4 g of iron [6]. In heme complexes, the redox state of iron can vary, with ferrous PPIX (or heme Fe 2+ complex) and ferric PPIX (or heme Fe 3+ complex) being the most common forms [7]. In summary of these properties, heme is gradually gaining widespread use as a bioavailable iron donor in industries such as healthcare and dietary supplements to treat many conditions, including iron deficiency anemia (IDA) in pregnant women [8,9] ( Figure 1).
Industrial demand for heme has surged in recent years, primarily due to the significant role heme plays in future foods such as artificial meat. In recent years, 3D printing, shear cell technology, and recombinant protein additives [10,11] used to enhance the sensory years, the strategies to achieve high heme production based on whole-cell systems, and the application of biosensors in this process.

Natural Biosynthetic Pathway of Heme
The biosynthesis of heme based on whole cell systems relies heavily on complex regulation in the heme biological pathway in microorganisms. To construct a more optimal heme synthetic pathway, the more genetic elements available in the cell factory, the better, and a comprehensive understanding of the heme synthetic pathway in nature is necessary.
Until 2010, the protoporphyrin-dependent (PPD) pathway was the only known heme biosynthetic pathway, and it was quite prevalent in traditional models of prokaryotes and eukaryotes such as E. coli, yeast, plants, and animals [30]. It has been assumed for a long time that all organisms synthesize heme through a similar PPD pathway [31] Unlike eukaryotes, bacteria, and archaea have multiple heme biosynthesis pathways, according to biochemical traces and bioinformatics studies since 1990. Currently, three pathways for heme synthesis are known to exist in nature. The PPD pathway is the most prevalent, but there are two others: the siroheme-dependent (SHD) pathway, the most ancient of the three, and the coproporphyrin-dependent (CPD) pathway, the least common of the three and found only in Gram-positive bacteria [1] Although they share some steps, their entry and exit points and molecular intermediates differ.

Synthesis of ALA
An essential precursor of heme and the first shared intermediate metabolite in the three heme synthesis pathways described above is ALA (PDD, SHD, CPD). The C4 ("Shemin") or C5 metabolic pathways are two ways microorganisms can produce them ( Figure 2).
The C4 pathway is predominantly found in fungi, α-amastigotes, and postnatal animals such as mammals [15,32], where the pyridoxal-5′-phosphate-dependent enzyme AlaS catalyzes the condensation of glycine and succinyl coenzyme A (CoA) to ALA, accompanied by the release of CO2 and coenzyme A as byproducts [33] (Figure 2).
The C5 pathway is the more common pathway of ALA synthesis in archaea, most bacteria, and plants. Compared to the C4 pathway, it is the more efficient and preferred

Natural Biosynthetic Pathway of Heme
The biosynthesis of heme based on whole cell systems relies heavily on complex regulation in the heme biological pathway in microorganisms. To construct a more optimal heme synthetic pathway, the more genetic elements available in the cell factory, the better, and a comprehensive understanding of the heme synthetic pathway in nature is necessary.
Until 2010, the protoporphyrin-dependent (PPD) pathway was the only known heme biosynthetic pathway, and it was quite prevalent in traditional models of prokaryotes and eukaryotes such as E. coli, yeast, plants, and animals [30]. It has been assumed for a long time that all organisms synthesize heme through a similar PPD pathway [31] Unlike eukaryotes, bacteria, and archaea have multiple heme biosynthesis pathways, according to biochemical traces and bioinformatics studies since 1990. Currently, three pathways for heme synthesis are known to exist in nature. The PPD pathway is the most prevalent, but there are two others: the siroheme-dependent (SHD) pathway, the most ancient of the three, and the coproporphyrin-dependent (CPD) pathway, the least common of the three and found only in Gram-positive bacteria [1] Although they share some steps, their entry and exit points and molecular intermediates differ.

Synthesis of ALA
An essential precursor of heme and the first shared intermediate metabolite in the three heme synthesis pathways described above is ALA (PDD, SHD, CPD). The C4 ("Shemin") or C5 metabolic pathways are two ways microorganisms can produce them ( Figure 2).
The C4 pathway is predominantly found in fungi, α-amastigotes, and postnatal animals such as mammals [15,32], where the pyridoxal-5 -phosphate-dependent enzyme AlaS catalyzes the condensation of glycine and succinyl coenzyme A (CoA) to ALA, accompanied by the release of CO 2 and coenzyme A as byproducts [33] (Figure 2).
The C5 pathway is the more common pathway of ALA synthesis in archaea, most bacteria, and plants. Compared to the C4 pathway, it is the more efficient and preferred pathway for heme manufacture in the industry due to its ability to obtain higher heme titers with a simple carbon source as a substrate [34][35][36]. In this pathway, there are three steps (Figure 2), glutamyl-tRNA is first obtained by transfer RNA (tRNA) binding to the five-carbon backbone of glutamate catalyzed by glutamyl-tRNA synthetase (gltX). Then, glutamyl-tRNA is converted to glutamine-1-semialdehyde catalyzed by glutamyl-tRNA reductase (hemA). Finally, it is then catalyzed by glutamate-1-semialdehyde transaminase (hemL) to produce ALA [30]. pathway for heme manufacture in the industry due to its ability to obtain higher heme titers with a simple carbon source as a substrate [34,35,36]. In this pathway, there are three steps (Figure 2), glutamyl-tRNA is first obtained by transfer RNA (tRNA) binding to the five-carbon backbone of glutamate catalyzed by glutamyl-tRNA synthetase (gltX). Then, glutamyl-tRNA is converted to glutamine-1-semialdehyde catalyzed by glutamyl-tRNA reductase (hemA). Finally, it is then catalyzed by glutamate-1-semialdehyde transaminase (hemL) to produce ALA [30]. Figure 2. The biosynthetic pathway of heme. The two biosynthetic pathways of 5-aminolevulinic acid (bolded to indicate its importance) are shown in green (C4 pathway) and red (C5 pathway). The three downstream synthetic pathways of heme are marked with blue (CPD), indigo (SHD) and purple (PPD). Solid lines indicate single reactions, and dashed lines indicate more than two reactions. The names of genes encoding the individual enzymes are in italics and some reactions have alternative genes. The abbreviations of the corresponding enzymes are shown in grey rectangle. See Table 1 for a list of names and abbreviations for heme synthesis enzymes.

Formation of Uroporphyrinogen III
The formation of uroporphyrinogen III, the second and last important common intermediate of the three heme downstream biosynthetic pathways, can be separated into three steps ( Figure 2). First, a homologous metalloenzyme, porphobilinogen synthase (PbgS), whose catalytic activity depends on metal ions (Zn 2+ in yeast, bacteria, and mammals or Mg 2+ in bacteria, and plants) promotes the asymmetric condensation of two ALA molecules to porphobilinogen [37]. Next, hydroxymethylbilane synthase (HmbS) is a monomeric enzyme whose catalytic activity normally depends on the bipyrrole methane cofactor. It catalyzes the condensation of four porphobilinogen molecules to generate hydroxymethylbilane. In the last step, uroporphyrinogen III synthase (UroS) catalyzes the cyclization of hydroxymethylbilane to produce uroporphyrinogen III [38] while promoting the molecular rearrangement of hydroxymethylbilane to avoid the formation of uroporphyrinogen I [39].

Three Downstream Heme Biosynthesis Pathways
The PPD pathway was the first to be discovered, and the related enzymes, and catalytic mechanisms, have been relatively more intensively explored [40,41]. In this pathway, uroporphyrinogen III undergoes a four-step catalytic reaction to obtain heme ( Figure 2). First, uroporphyrinogen decarboxylase (UROD) modifies the four acetate side chains of uroporphyrinogen III (decarboxylated) to generate coproporphyrinogen III (CPIII). Next, coproporphyrinogen III decarboxylase (CgdC) (eukaryotes and a few Gram-negative bacteria) or coproporphyrinogen III dehydrogenase (CgdH) (bacteria) catalyze the oxidative decarboxylation of the two propionate substituents on the pyrrole rings A and B of CPIII to the vinyl group of protoporphyrinogen IX [34]. The third step is the catalytic conversion of protoporphyrinogen IX to PPIX. Protoporphyrinogen IX oxidase (PgoX), a member of the FAD-containing superfamily of amine oxidases, acts in eukaryotes and some Gram-negative bacteria, whereas two protoporphyrinogen IX dehydrogenases (PgdH1 and PgdH2) act in most Gram-negative bacteria [42]. In the final step, protoporphyrin ferrochelatase (PpfC) catalyzes the insertion of ferrous iron into the macrocycle of protoporphyrin, allowing the conversion of PPIX to heme [43].
In the CPD pathway ( Figure 2), the first step reaction is identical to the PPD pathway and will not be described here ( Figure 2). Next, Coproporphyrinogen oxidase (CgoX), which acts similarly to the homologous enzyme (PgoX) in the PPD pathway, removes hydrogen atoms from CPIII through oxygen substitution to produce coproporphyrin III ( Figure 2). Interestingly, CgoX can catalyze CPIII while using protoporphyrinogen IX as a substrate [44]. Then, coproporphyrin ferrochelatase (CpfC) catalyzes the insertion of ferrous iron into the scaffold of coproporphyrin III, resulting in coproheme (also a common intermediate in the SHD pathway), a similar step to that catalyzed by PpfC in the PPD pathway ( Figure 2). Finally, coproheme decarboxylase (ChdC) decarboxylates the two propionates of the A and B rings of coproheme into vinyl, resulting in heme formation [34] ( Figure 2).
Finally, archaea, denitrifying bacteria, and sulfate-reducing bacteria first identified the SHD pathway ( Figure 2). It begins with precorin-2 synthesis from uroporphyrinogen III (the final common intermediate of the three-step reaction) commonly used in vitamin B12 synthesis immediately following the conversion of precorin-2 to sirohydrochlorin, which then serves as a substrate to produce sirohaem ( Figure 2). Subsequently, the decarboxylation of the acetate side chains on rings C and D, catalyzed by the enzymes AhbA and AhbB, produces 12,18-decarboxylated silicon hemoglobin. It is further removed by the AhbC protein, a deacetylase, from the acetate groups of the A and B rings to produce fecal heme ( Figure 2) [45]. Although the final step of the SHD and the CPD pathways are identical, they are catalyzed by two enzymes that have evolved completely independently: AhbD and HemQ, respectively [46]. SHD, the heme b synthase AhbD, a monomeric cytoplasmic protein [47], modifies the propionate side chains of the heme A and B rings to vinyl to produce heme.

Selection of Chassis Cells and Culture Methods
For whole-cell system-based heme production strategies, the final heme yield is highly influenced by the selection of chassis cells and the optimization of culture conditions. Different microorganisms have different background genomes, metabolic environments, and heme tolerance; consequently, the difficulty of constructing heme cell factories and the upper yield limit vary greatly between chassis cells. Chassis cells, the host where synthetic biological reactions occur, are the subject of some operations in genetic and metabolic engineering, and their selection is the basis and key to building an efficient cell factory.

Selection of Strains for Metabolic Regulation
Compared to plant and animal cells, microorganisms are the most suitable chassis cells for heme production through metabolic engineering due to their higher titer and productivity. Common microbial hosts include E. coli, Pichia pastoris, Saccharomyces cerevisiae, Corynebacterium glutamicum, Bacillus subtilis, and many others.

Escherichia coli
In the genome of E. coli, there are eight genes related to heme biosynthesis: hemB, hemC, hemD, hemE, hemF, hemN, hemG, and hemH ( Figure 2, Table 1). Due to its extremely low yield, the original strain heme is undetectable by common methods such as High-Performance Liquid Chromatography (HPLC).
According to the findings of Ge et al. [20], upregulation of hemB alone or simultaneously with hemB, hemG, and hemH significantly increased heme production. Moreover, increasing the copy number of hox1 encoding ferredoxin-dependent heme oxygenase (Hox1) and pcyA encoding phycocyanobilin: ferredoxin oxidoreductase (PcyA) promoted heme biosynthesis. In addition, Ju et al. [48] co-expressed ALA synthase (hemA), NADPdependent malic enzyme (maeB), and dicarboxylic acid transporter (dctA) in E. coli, producing recombinant E. coli capable of producing ALA and heme and serving as a bioavailable iron source. Due to the sophisticated and complex interacting heme production pathways, it is insufficient to regulate the expression of the relevant genes in a general way. To achieve fine regulation, Zhao et al. rechecked the overexpression of genes involved in the C5 pathway of ALA biosynthesis and key genes of downstream heme biosynthesis in plasmids [24] modularly combining the genes involved based on the previous rough regulation. Consequently, the titer of heme within the strain and the amount of free heme secreted at the extracellular level increased significantly.
In Saccharomyces cerevisiae, there is a natural spatial barrier to heme synthesis. Heme is synthesized in spatially isolated mitochondria and cytoplasm through eight (Hem1p, Hem2p, Hem3p, Hem4p, Hem12p, Hem13p, Hem14p, and Hem15p) enzymatic steps. Moreover, overexpression of HEM3 could significantly alleviate the rate-limiting effects in the biosynthesis process [21]. In addition, increasing the transcript levels of the HEM13, HEM14, and HEM15 genes also improves heme synthesis (Table 1) [49]. However, overexpression of Hem15 may cause oxidative damage and stress in cells due to increased mesoporphyrin [50]. In addition, Xue et al. [49] also demonstrated that Hem14p and Hem15p are efficient in generating heme from the intermediate product (protoporphyrinogen IX) in the cytoplasm and that a truncated assembly of Hem13p with Hem14p and Hem15p can effectively promote heme synthesis, resulting in heme that is sufficient for cell growth.
Diphtheria toxin repressor (DtxR), a global transcriptional regulator in Corynebacterium glutamicum, controls the expression of genes encoding membrane proteins and transcriptional regulators involved in iron storage, uptake, and utilization-related transcription.
Ko et al. [51] found that iron overload upregulated most heme biosynthetic pathway genes due to DtxR overexpression, which repressed the hrrA gene. The activation of HemA M and HemL proteins upregulated the complex and sophisticated heme biosynthetic pathway, increasing heme production in the engineered strain ratio of Growth rate was also restored, increasing total heme production [34].

Optimization of Cultivation Conditions
Over the past 30 years, strategies to improve the titers of ALA and heme by optimizing cultivation processes and investigating relevant medium components have received much attention.

Cultivation Conditions for ALA Production
ALA is an essential heme precursor, and enhancing its concentration through culture optimization is beneficial for heme production. The common ones are batch replenishment fermentation and two-stage fermentation techniques.
Due to the ionic effect on ALA synthase enzyme activity in normally supplemented cultures [52], the ionic composition of the culture broth plays a crucial role in ALA production during fermentation. Previous studies have demonstrated that Mn 2+ and Mg 2+ ion concentrations are crucial factors in E. coli ALA production [53]. Recently, Cui et al. [54] demonstrated that 1 g/L MgSO4-7H2O and 0.01 g/L MnSO4-7H2O in the culture medium were suitable for ALA production by E. coli. In addition, they also found that yeast extract affected ALA production, and while 12 g/L yeast extract promoted cell growth and ALA accumulation, lower levels significantly affected ALA production. Although yeast extract at 12 g/L promotes cell growth and facilitates ALA accumulation, lower concentrations of yeast extract are more suitable for large-scale industrial organisms production due to their lower cost.
Two-stage fermentation technology refers to two stages of biomass growth decoupling and product synthesis, with the first stage focusing solely on cell growth and the second stage immediately following focusing on product fermentation. The two stages of separation allow cellular resources to focus more on product synthesis, yielding vigorous productivity and higher yields. As a result of the research of Yang et al. [55], non-growing cells were used for two-stage fermentation in ALA production, and the relevant parameters were optimized by a homogeneous design. The cells were transferred to a fermentation buffer with added glucose and glycine after the first stage for the second stage of fermentation, and the yield of ALA obtained was nearly 1.67 times higher than that obtained with E. coli cultured by normal supplementation due to the simplicity of the buffer system.

Cultivation Conditions for Heme Production
In the biosynthesis of heme, each vitamin plays a different and irreplaceable role. For example, biotin maintains the level of the medium during gluconeogenesis and the citric acid cycle, nicotinic acid enhances precursor carbon supply, pantothenic acid is a substrate for CoA biosynthesis, and cobalamin is a coenzyme for various enzymatic reactions. Based on this background, Lee et al. [56] investigated the effect of adding major vitamins to the culture medium on heme production. The addition of the previously mentioned vitamins (0.01 mg biotin, 5 mg niacin, 1 mg pantothenic acid, 1.4 mg cobalamin per liter) to a medium containing phosphate buffer and bicarbonate resulted in not only a 2.5-fold increase in the growth rate of the bacteria but also a 2-fold increase in the final heme synthesis.
The final step of heme synthesis requires the participation of Fe 2+ , so supplementing the medium with Fe 2+ required for the biosynthesis process may enhance the heme production, commonly FeCl 2 [15] and FeSO 4 [57]. Zhao et al. [24] used the pH-stat technique to automatically add 200 mg L −1 of FeSO 4 ·7H 2 O to the fed solution when the pH surpasses a preset value. Therefore, the intracellular heme titer of recombinant E. coli increased from 13.9 ± 0.7 mg L −1 to 32.7 ± 0.7 mg L −1 , and the percentage of heme secreted into the extracellular compartment increased.
Since the synthesis of a heme molecule requires four nitrogen atoms, the addition of an additional nitrogen source to the medium has a significant effect on the heme yield. The experimental results of Zhao et al. confirmed this conclusion [24]. They added 5 g L −1 of (NH 4 ) 2 SO 4 to the supplement solution as an additional nitrogen source. Following fermentation, they found that the intracellular heme titer and the percentage of extracellular heme had increased. For this reason, Ko et al. [51] investigated the effect of adding common nitrogen sources (ammonium sulfate, tryptophan, ammonium chloride, and caseinate hydrolysate) to culture broth on heme production. The medium supplemented with 10 g L −1 tryptophan was more effective at producing heme.
Environmental factors also play a significant role in determining the efficiency and amount of heme production during culture. The appropriate temperature is conducive to the growth of the strain. Zhao et al. [24] lowered the culture temperature to 30°C, which is lower than the previous incubation temperature of 37 • C [48,58]. Similarly, Ko et al. [51] cultured recombinant E. coli at 30 • C with 10 mg/L FeSO 4 ·7H 2 O in the culture medium and obtained similar results.
Suitable chassis cells and culture conditions only play a minor role in using the whole cell system to produce heme, so further research is needed.

Synthetic Biology Strategies to Enhance Heme Production
The purpose of synthetic biology is to combine biology and engineering to create novel biological functions and systems not found in nature. Synthetic biology develops cell factories by introducing new non-native pathways to produce target compounds in optimized chassis strains [16]. The process usually follows a DBTL cycle. A commonly used optimization process has three steps: (1) direct optimization of the pathway in any possible way; (2) removal of competing activities; (3) application of global regulatory engineering [59]. The process allows for more versatile and standardized options for developing cell factories while accelerating cycle efficiency ( Figure 3) by modifying programmable synthetic biology tools [60] such as CRISPR-Cas for different purposes, including efficient genome engineering and modular assembly of complex biological systems with unique functions. Common strategies are shown in Figure 4 and Table 2. A synthetic biology-inspired approach based on a design, build, test and learn cycle. In the design phase, bioinformatics analysis of whole genome sequences is performed using genome mining computational tools. In the construction phase, genetic engineering tools are used to clone, assemble and reconfigure the desired biosynthetic pathways with genetic elements and circuits. Finally, novel, enhanced and diverse biosynthetic pathway structures with practical applications are screened.

Enhances the Ability to Produce the Important Precursor ALA.
As an essential precursor in heme biosynthesis, ALA significantly increases the ability to produce heme, which plays a crucial role. A synthetic biology-inspired approach based on a design, build, test and learn cycle. In the design phase, bioinformatics analysis of whole genome sequences is performed using genome mining computational tools. In the construction phase, genetic engineering tools are used to clone, assemble and reconfigure the desired biosynthetic pathways with genetic elements and circuits. Finally, novel, enhanced and diverse biosynthetic pathway structures with practical applications are screened.

Enhances the Ability to Produce the Important Precursor ALA
As an essential precursor in heme biosynthesis, ALA significantly increases the ability to produce heme, which plays a crucial role.

Supplementation of the Substrate Succinyl CoA
Succinyl CoA is one of the substrates of ALA; therefore, an increase in intracellular CoA may contribute to heme biosynthesis.
Many scholars have attempted to enhance the supply of succinyl coenzyme a by increasing the metabolic flux to the positive tricarboxylic acid (TCA) cycle. Oh-Hee Kwon et al. overexpressed the maeB encoding malic enzyme (MAE), which provides the precursor pyruvate for CoA, in E. coli. The coaA encoding pantothenate kinase (PANK) gene was also overexpressed to provide additional CoA for ALA synthesis, resulting in a 10% increase in ALA production [55] and a twofold increase in the final heme product [48]. Peng et al. [55] directly catalyzed the synthesis reaction of succinyl CoA and increased ALA production by approximately 6% by overexpressing odhA-sucB-lpd encoding 2-oxo-tartaric acid dehydrogenase in recombinant Bacillus glutamicus. In addition, Ge et al. [61] upregulated the upstream genes icd and pda of succinyl CoA in the TCA cycle and downregulated the downstream genes sucCD, which encodes succinyl CoA synthase, sdhAB, which encodes succinic dehydrogenase subunits AB, and sdhCD, to amplify the source of succinyl CoA, reduce its consumption, and increase the carbon flux to ALA. Subsequently, Ding et al. [62] also knocked out sucCD and sdhAB to block the conversion of succinyl CoA to other downstream metabolites. The experiment results revealed that only sucCD deletion significantly increased ALA titer (1.31 g/L), whereas sdhAB knockdown had no effect.

Reduced Secretion of ALA to the Extracellular
In addition, it is also possible to increase ALA titer by decreasing its secretion. Most cells still require transporter proteins to accelerate ALA export, although cells can metabolize ALA out of the cell spontaneously.
EamA is a non-specific amino acid transporter membrane protein [63], a major facilitator superfamily transporter, participating in ALA secretion. Feng et al. [64] knocked down eamA while ensuring the cell growth state. A decrease in ALA secretion led to a metabolic flux increase for downstream heme synthesis and a 42.9% increase in intracellular heme content.
In addition to eamA, Kang et al. discovered RhtA, an endosomal transporter protein encoded by the rhtA gene that effluxes isotopes and threonine with broad substrate specificity and accelerates ALA production in E. coli [65]. Following this, RhtA frequently functions as a non-specific transporter and plays a crucial role in the efficient production of ALA by E. coli as an extracellular [66]. In addition, many scholars have also introduced E. coli rhtA into Corynebacterium glutamicum as a more efficient and cost-effective strategy for producing extracellular ALA than E. coli [55,67,68]. Conversely, in the future, it may be possible to reduce ALA secretion to the extracellular compartment by down-regulating rhtA expression in E. coli, thereby enhancing the intracellular ALA titer and favoring heme production.

Regulation in the Heme Biosynthesis Pathway
Multiple genes in the heme biosynthetic pathway may be regulated to affect ALA titers and heme production; this pathway is complex and sophisticated, with meticulous relationships between various intermediate metabolites. Ju et al. [48] found that increased heme downstream synthesis pathway gene expression (hemC, hemD, hemE) could also increase ALA levels. Similarly, Zhang et al. [69] found a significant increase in ALA titer and cell biomass in recombinant E. coli overexpressing hemA, hemL, hemD, and hemF after 7.5 mg/L addition. These methods all facilitated the achievement of high heme production.
In addition, some metabolic regulatory strategies use heme production pathways to increase ALA titers, which is detrimental to end-product heme production by down-regulation downstream genes. For example, Tianyuan Su et al. [70] found that using CRISPR interference (CRISPRi) to down-regulate HemB expression, which is involved in heme biosynthesis, resulted in a significant increase in ALA accumulation but a decrease in heme production. Experiments conducted by Li et al. [57] demonstrated that sRNA RyhB inhibited the expression of iron-binding proteins and led to the down-regulation of the transcript levels of hemB and hemH, both increased ALA accumulation by 116%. However, there was a noticeable reduction in heme accumulation downstream of the heme biosynthesis pathway, and cell growth was also affected to some extent. Therefore, this strategy is also not suitable for heme production.
Although ALA as a precursor affects heme production, heme as a final product influences its level in a complex regulatory pathway. Feng et al. [64] heterologously expressed dye-decolorizing peroxidase (DyP), a heme peroxidase from Thermobifida fusca, to immobilize heme, thereby reducing free heme levels in cells and alleviating the feedback inhibition of ALA synthesis, which in turn promoted heme production. Similarly, Ge et al. [20] upregulated hemAs and hemL to promote ALA synthesis while reducing the feedback inhibition caused by heme accumulation, which had a similar effect on final heme production.

Other Regulations in TCA Cycle
Not only does the heme synthesis pathway influence ALA accumulation, but so do engineered metabolic fluxes from TCA cycles and the upstream.
By eliminating sucA from E. coli, Noh et al. [71] blocked the TCA cycle, accumulating α-ketoglutarate and allowing more carbon flux to flow ALA production, resulting in an 8.77-fold increase in ALA production. Associated intermediates are synthesized through the glyoxalate cycle when the TCA cycle is interrupted. However, excessive carbon flux may result in a shortage of α-ketoglutarate, which is required for ALA production, whereas insufficient carbon flux may impair cell growth due to a lack of essential metabolites such as succinate and oxaloacetate [54]. Consequently, aceA, which encodes isocitrate lyase, is crucial for precise carbon flux regulation in the glyoxalate cycle. Engineered E. coli with moderate AceA activity, obtained by altering transcriptional intensity, have abundant cellular biomass and high ALA production.
Interestingly, Ge et al. [61] found that in C. glutamicum, knockdown aceA directly alleviated competition between the glyoxylate and TCA cycles and increased ALA titers. In addition, they deleted gdhA, which encodes glutamate dehydrogenase, to reduce the carbon flux to glutamate, an unwanted metabolite, to increase ALA production.

Removing Competitive Pathways
With limited substrate, deleting the competing pathway allows carbon flux to flow to the target product, resulting in a more efficient production process and improved yields.
To remove the competitive pathway, Geng et al. [15] first knocked out cysG encoding sirohydrochlorin ferrochelatase and hemX encoding uroporphyrin-III C-methyltransferase in E. coli JM109(DE3), which is involved in extracellular transport of heme production precursors, to block Siroheme synthesis and increase heme titers. In addition, CyoE disruption prevented the conversion of hemeO, resulting in a dramatic increase in heme accumulation and production, while ALA production remained almost unchanged. Similarly, in E. coli, knockout of PTA, encoding the phosphate acetyltransferase that catalyzes acetate synthesis, and ldhA, encoding the lactate dehydrogenase that catalyzes lactate synthesis, ensured a metabolic flux from glucose to l-glutamate, resulting in a doubling of the amount of succinate produced and an accumulation of pyruvate and some citrate in the culture [72], which is beneficial for heme synthesis. Zhao et al. [24] confirmed that gene regulation in the heme pathway increased intracellular heme from 4.2 ± 0.6 mg L −1 , an increase over the 0.53 mg L −1 produced by control bacteria. In this study, yfeX, which encodes a peroxidase YfeX that catalyzes the production of porphyrins from porphobilinogen [23] and whose overexpression may disrupt heme homeostasis [73], was hypothesized to encode a putative heme-degrading enzyme that was also deleted in E. coli to enhance heme production.
whereas insufficient carbon flux may impair cell growth due to a lack of essential metabolites such as succinate and oxaloacetate [54]. Consequently, aceA, which encodes isocitrate lyase, is crucial for precise carbon flux regulation in the glyoxalate cycle. Engineered E. coli with moderate AceA activity, obtained by altering transcriptional intensity, have abundant cellular biomass and high ALA production.
Interestingly, Ge et al. [61] found that in C. glutamicum, knockdown aceA directly alleviated competition between the glyoxylate and TCA cycles and increased ALA titers. In addition, they deleted gdhA, which encodes glutamate dehydrogenase, to reduce the carbon flux to glutamate, an unwanted metabolite, to increase ALA production. Figure 4. Synthetic biology strategies to enhance heme production. Green, orange, and red color blocks indicate genes that need to be up-regulated, down-regulated, and knocked out, respectively.

Removing Competitive Pathways
With limited substrate, deleting the competing pathway allows carbon flux to flow to the target product, resulting in a more efficient production process and improved yields.
To remove the competitive pathway, Geng et al. [15] first knocked out cysG encoding sirohydrochlorin ferrochelatase and hemX encoding uroporphyrin-III Cmethyltransferase in E. coli JM109(DE3), which is involved in extracellular transport of heme production precursors, to block Siroheme synthesis and increase heme titers. In addition, CyoE disruption prevented the conversion of hemeO, resulting in a dramatic increase in heme accumulation and production, while ALA production remained almost unchanged. Similarly, in E. coli, knockout of PTA, encoding the phosphate acetyltransferase that catalyzes acetate synthesis, and ldhA, encoding the lactate dehydrogenase that catalyzes lactate synthesis, ensured a metabolic flux from glucose to l-glutamate, resulting in a doubling of the amount of succinate produced and an accumulation of pyruvate and some citrate in the culture [72], which is beneficial for heme Figure 4. Synthetic biology strategies to enhance heme production. Green, orange, and red color blocks indicate genes that need to be up-regulated, down-regulated, and knocked out, respectively.

Enhance the Secretion of Intracellular Free Heme
Previous studies have shown that direct overexpression of key genes in the heme synthesis pathway results in the accumulation of toxic and thus detrimental to cell growth byproducts, including porphyrins and the final heme product. Commonly, the secretion of intracellular free heme into the extracellular compartment is increased.
The general strategy is to enhance the secretory capacity of the membrane heme transporter. Zhao et al. [24] overexpressed a ccmABC gene encoding a potential heme exporter in engineered E. coli and detected an increase in total heme titer and extracellular heme percentage in the strain after fermentation. Similarly, Geng et al. [15] overexpressed Dpp in recombinant E. coli by gene editing techniques, resulting in a 2.08-fold increase in final heme production [15]. In addition, previous studies have demonstrated that cytochrome C exporter (CcsA) and transporter A (HrtA) and B (HrtB) in C. glutamicum reduce toxic heme concentrations and play a crucial role in extracellular heme secretion [74]. Experiments conducted by Ko et al. [51] demonstrated that although overexpression of the CcsA protein in C. glutamicum increased heme secretion in the strain, heme production and specific growth rate reduced significantly. Therefore, this strategy is inappropriate for heme production. In contrast, strains overexpressing the HrtA and HrtB transporter exhibited a 2.78-fold increase in heme secretion and did not exhibit this detection.
In addition, heme may be consumed during extracellular transport by binding to hemebinding proteins on the membrane. The heme-binding membrane proteins HtaA, HmuT, and HrrS in C. glutamicum are essential for heme biosynthesis regulation and secretion into the cytoplasm. Among these are HmuT, which regulates heme import [75], and HrrS, a histidine kinase that, when bound to exogenous heme, regulates heme homeostasis with HrrA, a heme manipulator transcriptional repressor [76]. Therefore, the engineered C. glutamicum obtained by Ko et al. [51] after generating absurd mutations in wild-type C. glutamicum using the CRISPR-cas12a system to disrupt the genes encoding the above three proteins not only reduced heme binding to membrane proteins but also promoted heme biosynthesis. The strains showed a heme secretion of 6.58 ± 0.63 mg L −1 and an even higher yield of 35.65 ± 0.67 mg L −1 when HrtA and HrtB transporter overexpression was combined with additional metabolic engineering. Knocking out sucCD to block the conversion of succinyl CoA to other downstream metabolites. [49]

C. glutamicum
Upregulating the expression of the upstream genes icd and pda of succinyl CoA while down-regulating the expression of the downstream genes sucCD and sdhABCD to amplify the source of succinyl CoA, reduce its consumption [21] Reduced secretion of ALA to the extracellular E. coli Knocking down eamA to reduce ALA secretion [72] Regulation in the heme biosynthesis pathway E. coli Heterologously expressing DyP to immobilize heme and alleviate the feedback inhibition of ALA synthesis [72] Enhancing expression of hemC, hemD, hemE in the downstream synthesis pathway of heme [14,75] Upregulating hemAs and hemL to promote ALA synthesis while reducing the feedback inhibition of heme [12] Other regulations in TCA cycle

E. coli
Eliminating sucA to block the TCA cycle result in accumulating α-ketoglutarate and thus allowing more carbon flux to flow to ALA production, [58] C. glutamicum Knocking down aceA and deleting gdhA to alleviate competition between the glyoxylate and TCA cycles and reduce the carbon flux to glutamate. [21] Removing competitive pathways E. coli Knocking out CysG and hemX to block the synthesis of Siroheme and knocking out CyoE to prevent conversion of heme to hemeO [77] Knocking out of pta catalyzing acetate synthesis and ldhA, that catalyzing lactate synthesis to ensure a metabolic flux from glucose to l-glutamate [78] Deleting yfeX to prevent disruption of heme homeostasis [79] Enhance the secretion of intracellular free Heme

E. coli
Upregulating ccmABC encoding a potential heme exporter [79] C. glutamicum Overexpressing the HrtA and HrtB transporter [54] Disrupt the HtaA, HmuT and HrrS by the CRISPR-cas12a system to reduce the binding of heme to membrane proteins [54]

Whole-Cell Biosensor in Heme Production
Heme, involved in electron transfer, oxygen storage, and enzymatic reactions, is essential for living organisms. However, excessive free heme concentrations in cells are toxic because they generate large amounts of reactive oxygen species. By causing irreversible damage to nucleic acids, proteins, and oxidized membranes, these reactive oxygen species create a pro-inflammatory environment detrimental to cell growth and heme production. Therefore it is necessary to monitor intracellular hemoglobin in real time [78,80].
Whole-cell biosensors can be used as a low-cost assay for the target instead of analytical instruments using quantifiable signals from reporter proteins to identify bioavailable levels of target analytes in various sample types with high specificity. Similarly, whole-cell biosensors play a crucial role in heme production [81].

Biosensor for ALA Detection
Using cell factories based on whole-cell systems for heme production sometimes involves a modular stepwise optimization strategy, such as optimizing ALA production first. Biosensors for detecting ALA enable high-throughput screening of experimental strains, vastly improving efficiency and allowing direct visual discrimination. As early as 2005, Chung et al. [82] tried to bind the green fluorescent protein gene (egfp) to hemA and use the green fluorescence intensity to respond to the ALA concentration. Although this enabled the characterization and study of extracellular ALA, the precise value of its concentration still relied on the Ehrlich reagent. On this basis, Tan et al. [83] fused super folder green fluorescent protein (sfGFP) to R. globosporus HemA (RshemA), using a dual promoter and dual plasmid, to detect and produce ALA simultaneously.
The above strategies involve binding fluorescent proteins to genes in the production pathway and indirectly responding to ALA production with the degree of gene transcription. The assumption underlying this practice is that the production of ALA is positively correlated with the expression of this gene. However, such strategies are infeasible for examining the relationship between ALA production and the expression profile of each gene in the biosynthetic pathway and their effect on heme production. Due to the structural similarity between ALA, glutamine, and asparagine, it is possible to modify the biosensors of these two amino acids to detect ALA. As previously shown, molecular docking techniques reduce the affinity for arginine and histidine while protecting the sensitivity of lysine through targeted saturation mutagenesis of the screened sites, thereby improving the biosensor sensitivity. Future attempts to modify sensors that respond to ALA analogs for its detection can use similar strategies [84].

Common Heme Detection Systems in Bacteria
There are innate heme-sensing systems in bacteria, which are paired with exocytosis proteins and then used to regulate heme homeostasis in bacteria to maintain their equilibrium. Common heme-sensing systems can be classified into one-and two-component systems ( Figure 5).

One-Component Systems
Saillant et al. [85] identified FhtR, a transcriptional regulator in Enterococcus faecalis that regulates heme homeostasis by governing an efflux pump named HrtBAEf, which, similar to HrtBA, regulates heme-dependent peroxidase A expression (KatA), thereby alleviating the oxidative stress produced by heme and reducing the toxicity caused by high heme concentrations.
HrtR is a transcriptional regulator in Lactobacillus lactis that senses and binds heme as its physiological effector to regulate the expression of the corresponding heme efflux system, stabilizing heme homeostasis [86]. Therefore, this appears to be more conserved in many commensal bacteria than the extracellular heme sensing system (HssRS) used by many Gram-positive bacteria. Separate from hrtR expression, hrtBA in this system is a potent heme sensor that regulates the response of the heme efflux pump, HrtBA, to maintain nontoxic intracellular heme levels [87]. equilibrium. Common heme-sensing systems can be classified into one-and twocomponent systems ( Figure 5).

Two-Component Systems
In Staphylococcus aureus, a two-component heme sensing system (HssRS) responds to exposed heme in real time and activates the corresponding heme transporter protein (HrtAB). Notably, in the absence of extracellular heme, endogenous heme synthesized by S. aureus is insufficient to activate HssRS, and the efflux protein HrtAB is not activated [88]. Subsequently, Stauff et al. [89] found using multivariate differential gel electrophoresis and mass spectrometry that S. aureus growth in high concentrations was linked to the signaling pathway between HssS (sensor histidine kinase) and HssR (response regulator). In addition, heme induction is dependent on direct repetitive DNA sequences within the hrtAB promoter [90]. Similarly, in heme-oxygen biosensors, the binding of oxygen to the heme-Fe 2+ complex in the oxygen-sensing globin domain induces autophosphorylation of its kinase domain through interdomain signal transduction. This type of protein is typically a component of a two-component signal transduction system and is able to respond to oxygen molecules [26,91].
This mechanism between the two-component heme sensing system (HssRS) and the heme detoxification transporter protein (HrtAB) is also present in Bacillus anthracis and is used to resist heme toxicity. Moreover, its sensitivity to heme is better, and its function is superior to its evolutionary relative, Staphylococcus aureus [92]. Similarly, in Bacillus thuringiensis, HssRS directly regulates a manipulator, hrmXY, encoding hypothetical membrane proteins, which differs from other strains of Firmicutes characterized by the HssRS and HrtAB systems. Moreover, the HrmXY function is independent of HrtAB and can mitigate heme toxicity differently [93].

Application of Heme Biosensor in Heme Production
As research on the above-mentioned bacterial endohemoglobin sensing systems continues, they are widely used in various aspects of heme elevation in microorganisms.
Establishing a mechanism to control cellular heme supply and demand is at the forefront of the heme production process. In this context, biosensors respond to the metabolite heme, balancing the proper input-output relationship, and are, therefore, responsible for this action. Leung et al. [94] fused ascorbate peroxidase (mAPX), a monomeric heme-binding peroxidase, with mEGFP, a monomeric form of green fluorescent protein, and developed a heme sensor (mAPXmEGFP) to monitor intracellular heme availability. Therefore, this also provides a mechanism for heme-based signaling and modulation.
As discussed in the previous section, "dynamic control" of metabolic pathways can largely enhance the ability of strains to produce high levels of heme. In this process, biosensors are essential for precise host metabolism regulation. Therefore, properties such as sensitivity, affinity, and tunability are crucial for heme production. Many scholars have produced many influential studies in these areas. For instance, Hu et al. [95] developed an optimal biosensor for the heme fine synthesis system in E. coli based on the heme-sensing monitoring system of L. lactis (HrtR regulator and its binding site hrtOL). They improved the sensitivity of HrtR and used it in combination with a small regulatory RNA system for fine-tuning heme levels in E. coli. Zhang et al. [96] used mutant biosensors with different binding affinities to influence the regulatory efficiency of the production pathway, thereby increasing ALA yield and successfully enhancing intermediate production, including protoporphyrinogen. Therefore, this offers new possibilities for more dynamic and precise regulation of the heme biosynthesis process and improvement of its yield.
Some other scholars have combined biosensors with other means to achieve greater possibilities. For example, Glanville et al. [28] first constructed a photosensitive pigment heme biosensor using a phytochrome-based fluorophore (PBF) protein (IFP1.4) and bacterial heme oxygenase (HO), then combined it with FACS and massively parallel sequencing to devise a histology-based method for metabolite-coupled transposon sequencing called "Met-Seq." However, they discovered previously unknown pathways and genes in Pseudomonas aeruginosa that may alter heme metabolism flux, identifying 188 genes that may impact intracellular heme levels. Hence, this provides new potential targets for future heme production improvements using metabolic regulation and other methods. In addition, through high-throughput screening, Mike et al. [97] identified VU0038882(882), a highly efficient small molecule activator of HssRS-dependent heme stress response. It is a useful tool for studying bacterial heme biosynthesis and central metabolism. In addition, the evaluation of the effects of possible gene regulation plays a crucial role in the effectiveness and efficiency of improving heme production. In this regard, Ishchuk et al. [98] used the enzyme-bound extension of the yeast 8 model (ecYeast8) to predict the optimal combination of these potential genes. Subsequently, combining a heme ligand binding biosensor (hemelbb) with a CRISPR-Cas9 toolbox developed for S. cerevisiae [99] to incorporate positive gene targets, the computationally determined combinations to enhance heme production were evaluated, resulting in a substantial increase in intracellular heme production.
Although heme-specific biosensors and their use in the efficient production of heme have been explored for many years, the technology is quite mature, and its applications are diverse. However, the design of biosensors targeting heme currently encounters three challenges [2]. First, due to the presence of heme in two oxidation states, namely reduced ferrous Fe 2+ -heme and oxidized ferric Fe 3+ -heme, it is not simple to improve the binding affinity of biosensors for heme. The next challenge is to adjust the probe expression of the heme biosensor to the appropriate level. Finally, consider whether the designed sensor expression will interfere with heme metabolism or other homeostasis and physiological processes. These challenges also indicate, to some extent, the need for future biosensor development efforts.

Application of Heme Protein and Its Derivatives in Various Fields
Because of its special structure and unique function, heme and heme-containing proteins are widely used in various fields, such as medical, supplements and food processing. The common ones are listed in Table 3.

Medical
The special structure of hemoglobin confers various functions that play a crucial role in the health and efficient functioning of the organism, offering new treatment possibilities for various diseases. By the bioactive gas-carrying capacity of hemoglobin, for example, Kazuaki Taguchi exogenously combined CO with liposomes of hemoglobin capsules to mimic the structure and function of red blood cells to obtain CO-HbV, which significantly inhibited pulmonary fibrosis and had a favorable therapeutic effect on idiopathic pulmonary fibrosis. Wang et al. [109] added hemoglobin, a chelating protein of free hemoglobin, to the storage of free hemoglobin, which could prevent the rapid loss of NO during storage, thereby improving the quality of transfused and stored red blood cells [101]. Moreover, heme proteins play an important role in the biosynthesis and related functions of NO, an important gas molecule in many diseases. The heme iron complex of hemoglobin and myoglobin is capable of producing NO from nitrate and nitrite anions. NO molecule can bind to both the heme-Fe 2+ complex and the heme-Fe 3+ complex at the same time, thereby eliminating its own toxicity to some extent [26].
In the external venous blood of mice, rat, and humans, hemoglobin can also react with nitric oxide to form iron nitroso complexes. These complexes can be used to monitor the progression of cardiovascular disease by directly quantifying bioavailable nitric oxide in human circulation using electron paramagnetic resonance spectroscopy. In addition, the results of Zhang et al. [103] showed that the βCys93 subunit in hemoglobin plays a crucial role in cardioprotection. They expanded their analysis of βCys93Ala animals to well-established experimental mouse models of myocardial infarction and cardiomyopathy, exploring the possibility that enhanced transmission of SNO-based vasodilatory activity of the βCys93 subunit in hemoglobin may predict improved oxygenation in heart failure and acute coronary syndromes, as well as tissue oxygenation physiology deficiencies, as a novel therapeutic strategy for other troublesome conditions.

Dietary Supplements
Hemoglobin, an inexpensive and effective source of heme iron, is absorbed by selective heme transporters and is unaffected by metal ions throughout the absorption process [110,111]. Therefore, heme iron is often used as an iron supplement to combat iron deficiency since it is more bioavailability to humans. A common strategy begins with processed foods fortification, such as fortifying staple foods with heme iron.
Michael Hoppe et al. [112] attempted to improve iron status in women of childbearing age using a blood-based dietary therapy. The second strategy is to use heme iron directly as a supplement capsule or tablet. For example, a heme-bound iron supplement tablet is commonly used to treat pregnant women with pregnancy-related IDA [8]. In addition, due to the high concentration of heme iron in bovine blood, bovine blood meal contains as much as 195.46 mg/100 g [113]. Bovine blood has been suggested as a low-cost source of heme iron. The heme iron prepared by Ningtang et al. [104] with bovine blood has strong antioxidant activity in vitro, has a good effect on iron deficiency anemia rats, and can be used as an efficient and safe new iron supplement.

Food Processing
Hemoglobin is a rich source of natural red colorants; however, its color is unstable and largely depends on the oxidative state of heme iron. Meat processing stabilizes hemoglobin using various techniques, such as adding the chelating agent nicotinamide to form a complex with heme [105], introducing saturated carbon monoxide (CO) to convert hemoglobin into carboxyhemoglobin, which is resistant to cooking and dehydration [114] or improving packaging.
With the continuous development of the artificial meat industry, the application field of hemoglobin as a colorant has gradually expanded. Impossible Foods Inc. (Redwood City, CA, USA) synthesized the LegHb c2 gene in soybeans and inserted it into Pichia yeast, a yeast host. The obtained LegHb protein passed the allergy and toxicity tests and can confer flavor characteristics on animal meat in plant meat products [107]. The direct addition of extracellular heme proteins to the growth medium during cell proliferation and differentiation improves the proliferation and metabolism of bovine skeletal muscle cells during cellular meat production [77]. Therefore, adding hemoglobin during 3D skeletal muscle tissue formation cultured in vitro of cellular meat can give it a more meat-like look and taste [12].
In addition, hemoglobin and nitrite can form nitroso hemoglobin. Additionally, research has demonstrated that the presence of heme promotes nitroso compound formation [100]. Nitrosohemoglobin can also be used as a colorant to improve the color of the emulsified intestine while simultaneously reducing nitrite residue and exerting a strong antioxidant effect. Therefore, it can replace nitrite as a natural pigment in the emulsified intestine, improving sensory qualities. However, nitroso hemoglobin is similar to hemoglobin but very unstable under air and light and easily degrades and fades. Therefore, people use synthesizing glycosylated nitroso hemoglobin method after glycosylation to improve its physical and chemical properties [115]. In 2019, glycosylated nitrosohemoglobin pigment had good solubility under vacuum freeze-drying and 60°C conditions, strong stability in −18°C storage indoor dark light, 15% hydrogen peroxide, and magnesium chloride solution, and was used to preserve pork. Hongtao Zhang et al. [116] added it to pork batter to help form the red color.
Globin has superior emulsifying ability, and Crenwelge et al. [79] found that globin has the best emulsifying ability after comparing it with soy, cottonseed, and milk protein.
The emulsifying activity value of globin with an EAI of 28 is much higher than that of soy protein (EAI of 14) and ovalbumin (EAI of 8). Therefore, globin is often added as a food emulsifier in minced meat or sausage preparation. In addition, globin can serve as a fat substitute. In a study conducted by Viana et al. [108], replacing fat with globin and plasma globin reduced the fat content of ham by 25% and 35%, respectively. Adding these fat substitutes increases the moisture and has been observed.
Similarly, PAS (Per-Arnt-Sim) domains are commonly used as signal sites for proteinprotein interactions and signal acceptance sites for intermolecular and intramolecular signal transduction [26]. PAS sensors recognize the presence of oxygen and activate genes associated with aerobic metabolism. These heme proteins have different oxygen affinities to suit their functional purposes [29].

Conclusions
Heme has been widely used in various fields due to its unique structure and indispensable biochemical function. Whole-cell system-based biosynthesis methods are being explored to meet the growing demand for heme.
First, in the past decade, the complex heme generation pathway (especially the newly discovered CPD and SHD pathway) and effector system in microorganisms have been studied, laying the foundation for biosynthesis and expanding research. Secondly, the strategies of efficient heme production by metabolic engineering and other means through various microorganisms as site cells are constantly enriched, and the optimization of culture conditions and technology has greatly improved the yield. In addition, wholecell-based biosensors and other new technologies in production are no longer limited to high-throughput screening due to synthetic biology and other fields. All these efforts pave the way for further exploration of the efficient production of heme by microorganisms in the future and point out potential new directions.